404928-18-3 Usage
Uses
Used in Pharmaceutical Industry:
2,6-dibromo-4-fluoro-benzonitrile is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and properties make it a key component in the development of new drugs, contributing to the advancement of medical treatments.
Used in Agrochemical Industry:
In the agrochemical sector, 2,6-dibromo-4-fluoro-benzonitrile is employed as an intermediate in the production of agricultural products. Its chemical characteristics are harnessed to create compounds that can be used in crop protection and other agricultural applications, thereby enhancing crop yields and quality.
It is important to handle 2,6-dibromo-4-fluoro-benzonitrile with care, as it can be toxic and harmful if not used properly. Proper safety measures and protocols should be followed to ensure the safe use of 2,6-dibromo-4-fluoro-benzonitrile in both pharmaceutical and agrochemical applications.
Check Digit Verification of cas no
The CAS Registry Mumber 404928-18-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,0,4,9,2 and 8 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 404928-18:
(8*4)+(7*0)+(6*4)+(5*9)+(4*2)+(3*8)+(2*1)+(1*8)=143
143 % 10 = 3
So 404928-18-3 is a valid CAS Registry Number.
404928-18-3Relevant academic research and scientific papers
Inhibitors of Bruton's Tyrosine Kinase
-
Page/Page column 125, (2010/09/07)
This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-III: wherein, variables Q, R, X, X′, Y1, Y2, Y2′, Y3, Y4, Y5, m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.
